Immunovia has been approved for listing on Nasdaq Stockholm. The approval is subject to customary conditions. Immunovia was previously listed on Nasdaq First North Premier.
 
First day of trading on Nasdaq Stockholm is scheduled for 3 April 2018, and the last day of trading on Nasdaq First North Premier is scheduled for 29 March 2018.
 
Baker McKenzie is acting as legal adviser to Immunovia in connection with the listing on Nasdaq Stockholm. Baker McKenzie's team consists mainly of Joakim Falkner, Per Blom, Henric Roth, Ian Gulam and Linnea Back.